News | July 08, 2010

Guidelines Created for Managing Heart Devices in Patients Nearing End of Life

July 8, 2010 – A new consensus statement released recently by the Heart Rhythm Society (HRS) offers guidance for managing cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting device deactivation. The HRS expert consensus statement was presented recently at Heart Rhythm 2010, the society’s 31st Annual Scientific Sessions, and the complete guidelines will be published in the July edition of HeartRhythm, the official journal of HRS.

The consensus statement was written in collaboration with representatives from the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM), the American Heart Association (AHA) and the European Heart Rhythm Association (EHRA).

For decades, CIEDs – pacemakers, implantable cardioverter-defibrillators (ICDs), and more recently cardiac resynchronization therapy (CRT) devices – have proven to save lives in various populations at risk of serious heart rhythm disorders. As indications for device therapy continues to expand, the population of patients with these devices continues to grow. The new consensus statement is the first to offer clinicians and industry guidance on the management of CIEDs in those patients at the end of their lives or requesting withdrawal of device therapy.

“The overall understanding of device deactivation varies, and addressing device management with patients nearing the end of their lives can be very uncomfortable for many clinicians,” stated lead author of the statement, Rachel Lampert, M.D., FHRS, Yale University School of Medicine in New Haven, Conn. “The goal of this document is to provide clinicians with an understanding of the ethical and legal principles underlying device deactivation as well as guidance on communication about device deactivation with patients.”

The Heart Rhythm Society brought together a diverse panel of experts to comprehensively address the legal, ethical and religious principles supporting device deactivation in patients who have made this decision. To address the topic, a multidisciplinary group was convened and consisted of electrophysiologists, patients and representatives from the fields of geriatrics, palliative care, psychiatry, nursing, law, ethics and divinity.

The consensus statement outlines common ethical and legal concerns related to withdrawing CIED therapies (device deactivation), a decision-making algorithm for withdrawing CIED therapies, how CIED-related ethical conflicts can be prevented and the rights and responsibilities of the clinician whose personal beliefs preclude his/her participation in device deactivation.

The new consensus statement presents several key points:
• A patient with decision-making capacity has the legal right to refuse or request the withdrawal of any medical treatment or intervention, regardless of whether he or she is terminally ill, and regardless of whether the treatment prolongs life and its withdrawal results in death.
• Legally and ethically, carrying out a request to withdraw life-sustaining treatment is neither physician-assisted suicide nor euthanasia.
• A clinician cannot be compelled to carry out an ethically- and legally-permissible procedure (i.e. CIED deactivation) that he or she personally views as in conflict with his/her personal values. In these circumstances, the clinician cannot abandon the patient but should involve a colleague who is willing to carry out the procedure.
• Any physician or center that implants CIEDs should have a clearly defined process to withdraw therapies at such a time that becomes appropriate.
• The deactivation process should include anticipation of symptoms and appropriate palliative care planning tailored to individual patients’ needs, as well as the needs of family members when appropriate.
For more information: www.heartrhythmjournal.com

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients
News | Heart Failure| July 14, 2017
A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current...
Overlay Init